Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)

Neumora Therapeutics reported data from its Phase 3 KOASTAL Program; the stock fell nearly 50%. NEW YORK, June 16, 2026 /PRNewswire/ -- Neumora Therapeutics (NASDAQ: NMRA) shareholders lost significant value today after the company disclosed that navacaprant failed both Phase 3 KOASTAL-2...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.